Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension

Learn more about:
Related Clinical Trial
Retrospective Study of Clinical Practice and Management of Imported Schistosomiasis in France Monitoring Schistosome Hybrids Under Under Praziquantel Pressure Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension Correlating Protection Against Malaria With Serum Profiles Against Plasmodium Falciparum Antigen Repertoires Prevalence of Chronic Kidney Disease (CKD) and Risk Factors in Sub-Saharan Africa S. Japonicum and Pregnancy Outcomes Artemisinin-based Combination Therapy-Intermittent Preventive Treatment (ACT-IPT) Trial Among Schoolchildren in Kassena-Nankana, Ghana Study of Safety and Immune Response of the Sm14 Vaccine in Adults of Endemic Regions L-praziquantel Orodispersible Tablets (L-PZQ ODT) in Schistosoma Infected Children The Effect of Praziquantel Treatment on Schistosoma Mansoni Morbidity and re-Infection Along Lake Victoria, Uganda Praziquantel in Children Under Age 4 Schistosoma Haematobium Infections and Praziquantel Antioxidant Supplements in the Reversal of Schistosomal Peri-portal Fibrosis Single-sex Controlled Human Schistosomiasis Infection: Safety and Dose Finding A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel)(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults Single-sex Female Controlled Human Schistosomiasis Mansoni Infection An Open Label Dose Finding Safety and Efficacy in Children and Infants Infected With Schistosomiasis (S.Mansoni) Schistosomiasis Effect on Response to Vaccines, Anaemia and Nutritional Status of Children of Northern Senegal Praziquantel-Pharmacokinetic Study Schistosomiasis in Women of Reproductive Age in Burkina Faso: Implications for Control Iron Supplementation in Schistosomiasis and Soil Transmitted Helminths Control Programmes in Zambia Schistosomiasis in Formal and Non-Formal Schools in Uganda: Implications for Control Programmes Using Community-Based Volunteers to Reach Non-Enrolled School Aged Children Through Community-Directed Treatment of Schistosomiasis in School-Aged Children in Rural Northern Ghana Sm-TSP-2 Schistosomiasis Vaccine in Healthy Ugandan Adults Clinical Trial of Bilhvax,a Vaccine Candidate Against Schistosomiasis A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults Treatment of Female Genital Schistosomiasis (FGS) With Praziquantel: A Proof-of-Concept Study Schistosomiasis in Senegal Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST) Childhood Schistosomiasis: a Novel Strategy Extending the Benefits/Reach of Antihelminthic Treatment Anti-Schistosomiasis Vaccine: Sm14 Phase 2b-Sn in School Children Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis Arachidonic Acid Treatment Against Schistosomiasis Infection in Children Detection of Schistosomiasis CAA in Travellers After High-risk Water Contact Evaluation of Strategies for Improved Uptake of Preventive Treatment for Intestinal Schistosomiasis Health Benefits of Repeated Treatment in Pediatric Schistosomiasis Seropositivity and Adverse Birth Events in Migrants From Bilharzia-endemic Areas Women and Children as the Focus for Control of Schistosomiasis Infections in the Irrigations Area of Burkina Faso

Brief Title

Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension

Official Title

Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension

Brief Summary

      Pulmonary arterial hypertension (PAH) is a severe, progressive and potentially fatal disease
      that impairs the pulmonary circulation and leads to right ventricular failure. One of the
      world most prevalent etiologies of PAH is schistosomiasis-associated pulmonary arterial
      hypertension (Sch-PAH). New drugs have emerged to treat other forms of PAH, but their
      benefits cannot be automatically translated for Sch-PAH patients, since this etiology was not
      included in the pivotal PAH trials. One of the most promising therapies for the treatment of
      PAH to emerge in recent years is selexipag, an oral IP receptor agonist, which acts on the
      prostacyclin pathway. The present study aims to evaluate the efficacy, safety and
      tolerability of selexipague for the treatment of schistosomiasis-associated pulmonary
      arterial hypertension.

Study Phase

Phase 2

Study Type


Primary Outcome

Pulmonary vascular resistance

Secondary Outcome



Pulmonary Hypertension



Study Arms / Comparison Groups

Description:  Selexipag will be up titrated for a period that will last 12 weeks (Phase 2). The initial dose will be 200 mcg of selexipag every 12 hours, with weekly dose increases of 200 mcg, up to the maximum dose of 1600 mcg every 12 hours or until the classic side effects of the prostacyclin pathway drugs (headache, mandibular pain), among others) arise. The dose will then be reduced by 200 mcg per dose, and this will be the maximum dose considered for that particular patient, maintained in Phase 3 (16 weeks).


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

October 15, 2020

Completion Date

March 31, 2022

Primary Completion Date

November 30, 2021

Eligibility Criteria

        Inclusion Criteria:

          -  Patients with symptomatic Sch-PAH. Sch-PAH diagnosis necessarily include the three
             criteria below

               1. Invasive confirmation of PAH, according to the criteria defined in the Pulmonary
                  Hypertension Sixth World Symposium: mean pulmonary artery pressure higher than 20
                  mmHg, at rest, and the presence of pulmonary vascular resistance (PVR) equal to
                  or greater than 3 W, and a pulmonary capillary pressure considered normal (equal
                  to or lower than 15 mmHg (1)).

               2. At least one epidemiological criteria for chronic schistosomiasis: patient from a
                  highly prevalent region for schistosomiasis or previous history of parasitic
                  treatment for schistosomiasis or the presence of Schistosoma mansoni eggs in the
                  patient's feces

               3. Evidence of long-term hepatosplenic involvement by schistosomiasis, via
                  compatible ultrasound findings (peri-portal fibrosis or enlarged left lobe) All
                  patients will necessarily already be receiving at least one specific treatment
                  for PAH, either with phosphodiesterase V inhibitor or with an endothelin receptor
                  antagonist, with a stable dose for at least 12 weeks before inclusion in the

                  Exclusion Criteria:

          -  Patient without clinical condition to perform the 6-minute walk test

          -  Patient with gastro-intestinal bleeding for over 12 weeks




18 Years - N/A

Accepts Healthy Volunteers



Caio J Fernandes, PHD, 005511992149574, [email protected]

Location Countries


Location Countries


Administrative Informations



Organization ID


Responsible Party


Study Sponsor

University of Sao Paulo General Hospital


 Janssen-Cilag Ltd.

Study Sponsor

Caio J Fernandes, PHD, Principal Investigator, USP

Verification Date

October 2020